Keen Vision Acquisition Corporation Ordinary Shares KVAC
11.51 USD 0.00 (+0.00%)
At closeJul 31, 2026, 4:00 PM EDT
12.18 +0.67 +5.82%
After hours · Jul 31, 4:00 PM ET
11.51 Day range 12.00
52-week range unavailable
- YTD
- -2.04%
- 1 year
- +1.05%
- Market cap
- 212.06M
- Shares out
- 19.37M
- YTD return
- -2.04%
- 1-year return
- +1.05%
- Volume
- 35.17K
- Open
- 11.93
- Previous close
- 11.51
- Day's range
- 11.51 – 12.00
No chart data for this range yet.
Key statistics
- Enterprise value
- 212.12M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 40.50K
- Total debt
- 100.00K
- Return on equity
- 0.00%
- Short % of float
- 0.01%
- 50-day average
- 10.86
- 200-day average
- 10.66
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
KVAC Revenue — quarterly 0
KVAC Net income — quarterly 92.09K
KVAC EPS — quarterly -0.03
About Keen Vision Acquisition Corporation Ordinary Shares
Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.
- Sector
- Financial Services
- Industry
- Shell Companies
- Country
- United States
- Website
- kv-ac.com
News
Financial Comparison: Blaize (NASDAQ:BZAI) and Keen Vision Acquisition (NASDAQ:KVAC) 
Keen Vision Acquisition (NASDAQ:KVAC) Shares Up 0.9% – Here’s What Happened 
65,256 Shares in Keen Vision Acquisition Corporation $KVAC Acquired by Crossingbridge Advisors LLC 
Keen Vision Acquisition (NASDAQ:KVAC) Stock Price Up 0.1% – Time to Buy? 
Keen Vision Acquisition (NASDAQ:KVAC) Trading 0.5% Higher – Still a Buy? 
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025 
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress 
Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit 
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction 
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
Your note
Sign in to keep a note on KVAC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Trust Capital Management L.P. | 7.44% | 1,441,000 | 15.78M | Sep 29, 2024 |
| Karpus Management, Inc. | 7.09% | 1,372,585 | 15.03M | Sep 29, 2024 |
| Mizuho Securities USA LLC | 6.99% | 1,353,000 | 14.82M | Sep 29, 2024 |
| Berkley W R Corp | 4.92% | 952,209 | 10.43M | Sep 29, 2024 |
| Wolverine Asset Management, LLC | 4.57% | 885,388 | 9.69M | Sep 29, 2024 |
| Cowen and Company, LLC | 4.13% | 799,000 | 8.75M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Investment Managers Ser Tr II-First Trust Merger Arbitrage Fd | 7.21% | 1,396,579 | 15.29M | Sep 29, 2024 |
| Merger Fund, The | 3.22% | 622,800 | 6.82M | Sep 29, 2024 |
| CrossingBridge Pre-Merger SPAC ETF | 1.32% | 255,847 | 2.80M | Sep 29, 2024 |
| Calamos Market Neutral Income Fund | 0.52% | 100,000 | 1.09M | Oct 30, 2024 |
| Investment Managers Ser Tr II-First Trust Multi-Strategy Fd | 0.16% | 30,250 | 331.24K | Sep 29, 2024 |
| High Income Securities Fund | 0.15% | 28,469 | 311.74K | Aug 30, 2024 |